Scynexis Inc (SCYX) - Total Liabilities
Based on the latest financial reports, Scynexis Inc (SCYX) has total liabilities worth $9.65 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore SCYX cash generation efficiency to assess how effectively this company generates cash.
Scynexis Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Scynexis Inc's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Scynexis Inc to evaluate the company's liquid asset resilience ratio.
Scynexis Inc Competitors by Total Liabilities
The table below lists competitors of Scynexis Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Heimstaden AB Pfd.
ST:HEIM-PREF
|
Sweden | Skr236.74 Billion |
|
Dividend Select 15 Corp
TO:DS
|
Canada | CA$539.39K |
|
Swiss Properties Invest A/S
CO:SWISS
|
Denmark | Dkr451.79 Million |
|
Star Equity Holdings Inc
NASDAQ:STRR
|
USA | $49.37 Million |
|
Citigold Corporation Ltd
AU:CTO
|
Australia | AU$21.77 Million |
|
AKKO Invest Nyrt
BUD:AKKO
|
Hungary | Ft33.65 Billion |
|
FERRO-ALLOY RES.
F:5PE
|
Germany | €21.78 Million |
|
Mas Murni Indonesia Tbk
JK:MAMI
|
Indonesia | Rp534.06 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Scynexis Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Scynexis Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scynexis Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scynexis Inc (2012–2025)
The table below shows the annual total liabilities of Scynexis Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $9.65 Million | -72.86% |
| 2024-12-31 | $35.57 Million | -35.86% |
| 2023-12-31 | $55.45 Million | -34.44% |
| 2022-12-31 | $84.58 Million | +7.63% |
| 2021-12-31 | $78.58 Million | -1.50% |
| 2020-12-31 | $79.78 Million | +80.26% |
| 2019-12-31 | $44.26 Million | +101.68% |
| 2018-12-31 | $21.95 Million | -10.21% |
| 2017-12-31 | $24.44 Million | -2.13% |
| 2016-12-31 | $24.97 Million | +240.97% |
| 2015-12-31 | $7.32 Million | +17.35% |
| 2014-12-31 | $6.24 Million | -70.48% |
| 2013-12-31 | $21.14 Million | -32.78% |
| 2012-12-31 | $31.45 Million | -- |
About Scynexis Inc
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory inva… Read more